The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: Systematic review and network meta-analysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 6, 2012, Pages 611-627

  Cohen, Alexander ^a   Drost, Pieter ^b   Marchant, Nick ^c   Mitchell, Stephen ^d   Orme, Michelle ^e   Rublee, Dale ^f   Simon, Teresa A ^b   Sutton, Alex ^g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Decision Resources Group   (United Kingdom)

^e Icera Consulting   (United Kingdom)

^f PFIZER INC   (United States)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

anticoagulants; deep venous thrombosis; factor Xa inhibitors; pulmonary embolism; thrombosis prophylaxis; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BEMIPARIN; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; REVIPARIN; RIVAROXABAN; SEMULOPARIN; TINZAPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; EMBOLISM PREVENTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84863477329     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612437579     Document Type: Review

References (59)

1. The Prevention of Venous Thromboembolism in Hospitalised Patients. 2nd Report of Session 2004-05. HC99. London, UK: The Stationary Office Limited ; 2005 :
2. Deitelzweig SB, McKean SC, Amin AN, Brotman DJ, Jaffer AK, Spyropoulos AC. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med. 2008 ; 75 (suppl 3). S27 - S36
3. Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 381S - 453S (Pubitemid 351894916)
4. NICE Clinical Guidance 92. Venous Thromboembolism: Reducing the Risk. Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital. London: National Institute for Health and Clinical Excellence ; 2010 :
5. Eriksson BI, Borris LC, Friedman RJ. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 ; 358 (26). 2765-2775 (Pubitemid 351930851)
6. Eriksson BI, Dahl OE, Rosencher N. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 ; 5 (11). 2178-2185 (Pubitemid 47617868)
7. Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 ; 370 (9591). 949-956 (Pubitemid 47393577)
8. Kakkar AK, Brenner B, Dahl OE. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9632). 31-39
9. Lassen MR, Ageno W, Borris LC. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 ; 358 (26). 2776-2786 (Pubitemid 351930852)
10. Turpie AG, Lassen MR, Davidson BL. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009 ; 373 (9676). 1673-1680
11. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011 ; 62: 41-57
12. Wong PC, Crain EJ, Xin B. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008 ; 6 (5). 820-829 (Pubitemid 351524543)
13. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 ; 363 (26). 2487-2498
14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 ; 375 (9717). 807-815
15. Ades AE, Sculpher M, Sutton A. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006 ; 24 (1). 1-19 (Pubitemid 43197227)
16. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005 ; 331 (7521). 897-900 (Pubitemid 41502718)
17. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008 ; 11 (5). 956-964
18. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004 ; 23 (20). 3105-3124 (Pubitemid 39334902)
19. Harris R, Bardburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed-and random-effects meta-analysis. Stata J. 2008 ; 8 (1). 3-28
20. Stata J. 2008 ; 8 (1). 3-28
21. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997 ; 50 (6). 683-691 (Pubitemid 27341818)
22. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001 ; 10 (4). 277-303 (Pubitemid 32691157)
23. Spiegelhalter DJ, Abrams KR, Myles JP Bayesian Approaches to Clinical Trials and Health Care Evaluation. Chicester, England: Wiley ; 2004 :
24. The BUGS Project. http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml. Accessed February 8, 2011.
25. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007 ; 5 (12). 2368-2375 (Pubitemid 350154345)
26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 ; 361 (6). 594-604
27. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001 ; 345 (18). 1305-1310
28. Eriksson BI, Dahl OE, Buller HR. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 ; 3 (1). 103-111 (Pubitemid 41647122)
29. Eriksson BI, Kalebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991 ; 73 (4). 484-493
30. Eriksson BI, Wille-Jorgensen P, Kalebo P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997 ; 337 (19). 1329-1335 (Pubitemid 27467766)
31. Eriksson BI, Borris L, Dahl OE. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006 ; 4 (1). 121-128
32. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci. 2008 ; 13 (5). 442-451
33. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop. 2008 ; 32 (4). 443-451 (Pubitemid 351904622)
34. Hull RD, Pineo GF, Francis C. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000 ; 160 (14). 2199-2207 (Pubitemid 30482728)
35. Huo M, Eriksson BI, Dahl OE, et al. Oral Dabigatran Versus Enoxaparin for Thromboprophylaxis after Primary Total Hip Arthroplasty: The RENOVATE-II Randomised Trial (abstract). Presented at: European Hematology Association; 2010 October 22-24, 2010; Beirut, Lebanon.
36. Kakkar VV, Howes J, Sharma V, Kadziola Z. A. comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin assessment group. Thromb Haemost. 2000 ; 83 (4). 523-529 (Pubitemid 30201124)
37. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002 ; 359 (9319). 1715-1720 (Pubitemid 34607083)
38. Lassen MR, Dahl OE, Mismetti P, Destree D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study. J Thromb Haemost. 2009 ; 7 (4). 566-572
39. Lassen MR, Agnelli G, Fisher W, et al. The Ultra-Low- Molecular-Weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) After Elective Knee Replacement Surgery. 21st International Congress on Thrombosis; 2010; Milan, July 6-9, Italy.
40. Leclerc JR, Geerts WH, Desjardins L. Prevention of deep vein thrombosis after major knee surgery-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992 ; 67 (4). 417-423
41. Leclerc JR, Geerts WH, Desjardins L. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996 ; 124 (7). 619-626
42. Levine MN, Hirsh J, Gent M. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991 ; 114 (7). 545-551
43. Mouret P, Agnelli G, Fisher W, et al. The Ultra-Low-Molecular- Weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) after Elective Hip Replacement Surgery (abstract). 21st International Congress on Thrombosis; 2010; Milan, July 6-9, Italy.
44. Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost. 2003 ; 1 (3). 425-432
45. Eriksson BI, Borris LC, Dahl OE. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006 ; 114 (22). 2374-2381 (Pubitemid 44847454)
46. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001 ; 344 (9). 619-625 (Pubitemid 32183576)
47. Planes A, Vochelle N, Fagola M. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. Acta Chir Scand Suppl. 1990 ; 556: 108-115
48. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis. 1998 ; 9 (6). 499-505 (Pubitemid 28508791)
49. Planes A, Samama MM, Lensing AW. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999 ; 81 (1). 22-25 (Pubitemid 29041643)
50. Ginsberg JS, Davidson BL, Comp PC. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 ; 24 (1). 1-9
51. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar study group. Br J Anaesth. 1997 ; 78 (6). 660-665 (Pubitemid 27268074)
52. Spiro TE, Johnson GJ, Christie MJ. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin clinical trial group. Ann Intern Med. 1994 ; 121 (2). 81-89 (Pubitemid 24203489)
53. Torholm C, Broeng L, Jorgensen PS. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br. 1991 ; 73 (3). 434-438
54. Turpie AG. Enoxaparin prophylaxis in elective hip surgery. Acta Chir Scand Suppl. 1990 ; 556: 103-107
55. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002 ; 359 (9319). 1721-1726 (Pubitemid 34607085)
56. Turpie AG, Fisher WD, Bauer KA. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. J Thromb Haemost. 2005 ; 3 (11). 2479-2486 (Pubitemid 41727165)
57. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism-systematic review and adjusted indirect comparison. J Clin Pharm Ther. 2011 ; 36 (1). 111-124
58. Selby R, Geerts W. Prevention of venous thromboembolism: consensus, controversies, and challenges. Hematol Am Soc Hematol Educ Program. 2009 ;: 286-292
59. Squibb B-M Summary of Product Characteristics (SmPC) (Draft). Apixaban. Data on File. 2010.